Science AI Journal
Materials Science · Research topic

Open research questions in Nanoparticle-Based Drug Delivery

43 unresolved questions extracted from the limitations and future-work sections of 437 Nanoparticle-Based Drug Delivery papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • research should incorporate the AI assisted design of nanobot structures, personalized lung cancer therapy approaches, CRISPR based gene editing payloads, more sophisticated biomimetic designs and multi functional theranostic platforms that diagnose and treat simultaneously. If artificial intelligence, synthetic biology, nanotechnology and precision medicine continue to converge, then the evolved intelligent nanobots could plausibly reach the point of diagnosing, treating and monitoring lung cancer. However, the pace of progress in this field suggests the possibility of nanobots clinical application. More clinical trials involving nanobots could potentially explain its functioning inside the human body. Some early results show that the nanobots are capable of detecting 12 cancer cells at a time. This review has intentionally stayed at the level of theory and concept rather than original experimental work. We began with an overview of nanobots construction and mechanisms of action as they apply specifically to lung cancer treatment [1-10,16]. As a whole, it appears that nanobots are likely to become a meaningful part of drug delivery and diagnostic landscape for lung cancer therapy. REFERENCES 1. Carrasco-Esteban, E., Dominguez-Rullan, J. A., Barrionuevo-Castillo, P., Pelari-Mici, L., Leaman, O., Sastre-Gallego, S., & Lopez-Campos, F. (2021). Current role of nanoparticles in the treatment of lung cancer. Journal of Clinical and Translational Research, 7(2), 140-155. 2. Koutu, V., Gupta, M., Das, S., Rawat, D. K., Kharade, V., & Pasricha, R. K. (2023). Nanotechnology in lung cancer therapeutics: A narrative review. Cureus, 15(1), e34245. 3. Sheikh, M., & Jirvankar, P. S. (2024). Harnessing artificial intelligence for enhanced nanoparticle design AIMS Bioengineering, 11(4), 574-597. oncology. precision in 4. Halim, P., Tan, M. W., Yumiko, Lu, F. C., Dalimunthe, A., Tallei, T. E., Rahman, M., Rani, A., Kim, B., Maciel de Azambuja Ribeiro, R. I., & Syahputra, R. A. (2026). Nanotechnology in lung cancer: Enhancing targeted drug delivery and in Surfaces and diagnostic precision. Results Interfaces, 23, Article 100773. 5. Khan, Z., Khan, N., Geetha, M., Veettil, R. P., Kasote, D. M., Hasan, A., & Sadasivuni, K. K. (2025). Therapeutic applications of nanobots and treatment. Analytical nanocarriers Sciences, 41(8), 1305-1324. in cancer IOASD Journal of Medical and Pharmaceutical Sciences | Published by IOASD Publisher | India | 138 6. Dey, R. K., Jana, B., & Dastidar, D. G. (2023). Applications of nanotechnology in the treatment of pulmonary diseases. Vessel Plus, 7, 17. 7. Subramaniam, S., Donnellan, L., Wignall, A., Woodcock, J., Coolen, C., Pitson, S., Taheri, A., Young, C., Hoffmann, P., Prestidge, C. A., & Joyce, P. that (2025). Polymeric-lipid nanoparticles leverage cationic helper lipids and the protein corona for lung-targeted delivery of a novel anticancer drug. Journal of Controlled Release, 388(Part 1), 114299. 8. Pradeep, P., Sonia, M. M. L., & Kizhakkepeedika, R. D. (2024). Nanobots in cancer treatment– Framing lung cancer. Journal of Advanced Lung Health, 4(2), 57-69. 9. Lee, H., Sajid, K., & Lee, J. (2025).

    Nanobots in Lung Cancer Therapy: An Overview · 2026 · DOI

  • Conventional systemic chemotherapy is limited by the blood–brain barrier (BBB), systemic toxicity, and insufficient drug penetration into the tumor microenvironment.

    Integrating Endovascular Drug Delivery into the Therapeutic Landscape of Glioblastoma · 2026 · DOI

  • Future research should focus on:  Personalized nanomedicine  Biodegradable nanocarriers  AI-assisted formulation development  Precision-targeted therapeutics  Regulatory harmonization www.wjaps.com 23 World Journal of Advance Pharmaceutical Sciences WJAPS, Volume 3, Issue 7, 2026 A…

    NANOPARTICLES AS TARGETED DRUG DELIVERY SYSTEMS: RECENT ADVANCES AND FUTURE PERSPECTIVES · 2026 · DOI

  • Sonam Vishwakarma, Mahak Shukla, *Rupesh Kumar Jain, Vivek Jain, Muskan Lodhi Adina Institute of Pharmaceutical Sciences, Sagar, (M.P) 470002, India. Article Received on: 13/05/2026 Article Revised on: 03/06/2026 Article Published on: 01/07/2026 *Corresponding Author Dr. Rupesh Kumar Jain Professor, Adina Institute of Pharmaceutical Sciences, Sagar.

    LIPOSOMES AGAINST ALZHEIMER'S DISEASE: CURRENT RESEARCH AND FUTURE PROSPECTS · 2026 · DOI

  • of Neuroprotective Agents-Loaded Nanoparticles and Biomimetic Material in Ischemic Stroke, Frontiers in Cellular Nanoscience, 2022. 12.

    MN₃O₄@NANOERYTHROCYTE-T7 PEPTIDE: A BIOMIMETIC NANOPLATFORM FOR TARGETED ISCHEMIC STROKE THERAPY · 2026 · DOI

  • The future prospects for drug delivery systems using nanotechnology appear to be vast as researchers are actively working towards better targeting, accuracy, safety and clinical application of these systems. Newer techniques and focus on developing smart that can be activated upon specific nanoparticles physiological temperature, stimuli enzymes, magnetic fields etc. Such smart systems deliver drugs only at target disease site, reduce tissue toxicity and increase therapeutic outcome. Apart from this, development of better targeting methods, gene therapy, mRNA therapeutics and biomimetic nanocarriers are all expected to enhance treatment options for cancer, infectious and genetic neurodegenerative diseases, disorders. The application of AI and machine learning tools may also speed up the design of more efficient and personalized nanomedicine systems. including pH, Despite great advancements, in the future challenges of scale production, safety over long term, regulatory approval and cost efficiency will need to be conquered. breakthroughs More attention will be paid to biodegradable and green nanomaterials that will also show minimal toxicity and biocompatibility. Moreover, in nanotheranostics (dual function of imaging and therapy) will further advance the real-time disease monitoring and the tailor-made pharmaceutical regulatory authorities and industry would also be vital to translate promising nanotechnology from benchtop to bed. With these challenges being successfully addressed, nanodrug delivery systems will find their prominent place in the future of personalized and sophisticated healthcare.[37] treatment options. Partnership of clinicians, scientists, CONCLUSION The application of nanotechnology based drug delivery systems have revolutionized in pharmaceutical sciences as it provides new strategies to solve various drawbacks faced by traditional drug delivery systems. With the use of nanocarriers, these systems exhibit better solubility, stability, bioavailability and therapeutic activity as well as control the delivery and targeted administration of liposomes, drugs. A lipid nanoparticles, polymeric nanoparticles, solid dendrimers and biological nanocarriers have showed promising results in improving treatment of numerous diseases. It has been proved that nanoparticles can facilitate delivery across biological barriers, shield the therapeutic molecule from degradation, and also ensure site specific delivery leading to significant advancement in the field of modern therapeutics and patient focused medicine. range of nanocarriers, like Despite this progress, the difficulties in large scale manufacturing, long term safety, stability, reproducibility and regulatory approval, still affect their clinical translation. Research are actively ongoing to engineer nanocarriers that are safer, degradable, more efficient and target specific. Various cutting-edge nanomedicine technologies are being developed such as stimuli responsive nanoparticles, theranostic platforms, gene therapy, artificial intelligence in nanomedicine design. All these technological advancement are likely to broaden the application of nanotechnology in medicine. As our scientific knowledge and technology are ever advancing, nanomedicine is considered as a promising strategy that will serve as a core pillar in precise medicine, future pharmaceuticals development. personalized therapy and REFERENCES 1. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules, Sep. 29, 2021; 26(19): 5905. 2. Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk Ł, Hasanin MS, Kattali M, Haponiuk J, Thomas S. Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials (Basel), Jan.31; 2023; 13(3): 574. 3. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier Drug Delivery Systems: www.wjahr.com │ Volume 10, Issue 7, 2026 │ ISO 9001:2015 Certified Journal │ 53 Vasanth et al. World Journal of Advance Healthcare Research Characterization, Limitations, Future Perspectives and Intelligence.

    A REVIEW ON NANOTECHNOLOGY BASED DRUG DELIVERY SYSTEM · 2026 · DOI

  • Work on multifunctional nanoplatforms that engage the TME has built a substantial experimental foundation, but remains constrained by data fragmentation, manufacturing complexity and biological heterogeneity. Future developments are therefore more likely to reorganize and simplify within existing frameworks than to continuously add new functional layers to individual particles. Yang et al.

    Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy · 2026 · DOI

  • A limitation of this study is the absence of drug-free nanoparticles in DSC and XRD analyses, which would have provided clearer differentiation between polymer and drug-related thermal and crystalline transitions.

    Formulation of 5-fluorouracil loaded chitosan-based nanoparticles and evaluation of its cytotoxic effects against MCF-7 human breast cancer cells · 2026 · DOI

  • FST-loaded LPHNPs demonstrated Higuchi diffusion-controlled release kinetics at pH 7.4, but release behavior under acidic gastric conditions (pH 1.2-3.0) relevant to oral bioavailability and the impact of simulated intestinal fluid composition on the diffusion-regulated mechanism have not been evaluated.

    Multifunctional Lipid Polymer Hybrid Nanocarriers in Cancer Therapy: Recent Developments and Challenges · 2026 · DOI

  • Nanoparticle powders in the 70-110 nm size range exhibited poor aerodynamic properties for direct pulmonary administration; while the NiM strategy with spray-drying was applied to address this, the optimal microparticle dissolution kinetics in simulated lung fluid and the critical particle size range for efficient respiratory epithelium deposition have not been systematically defined.

    Multifunctional Lipid Polymer Hybrid Nanocarriers in Cancer Therapy: Recent Developments and Challenges · 2026 · DOI

  • Different RU-loaded LPH NP formulations exhibited distinct tissue distribution patterns (TPGS-LPH Fr=1.13 liver, Solutol-LPH Fr=0.94 liver, Tween-LPH Fr=2.26 liver), but the relationship between surfactant composition and organ-specific biodistribution in spleen and kidney has not been mechanistically characterized.

    Multifunctional Lipid Polymer Hybrid Nanocarriers in Cancer Therapy: Recent Developments and Challenges · 2026 · DOI

  • RU-loaded LPH nanoparticles with Solutol and TPGS surfactants showed enhanced brain bioavailability with highest AUC and Cmax in brain tissue, but the specific brain-targeting mechanism (receptor-mediated transcytosis, P-gp efflux inhibition, or tight junction modulation) remains unelucidated across the three surfactant formulations.

    Multifunctional Lipid Polymer Hybrid Nanocarriers in Cancer Therapy: Recent Developments and Challenges · 2026 · DOI

  • Roflumilast-loaded Man-LPHFNPs with nano-in-micro (NiM) delivery strategy achieved appropriate lung deposition particle sizes, but in vivo pulmonary bioavailability, mucociliary clearance resistance, and bronchial epithelial distribution kinetics have not been quantified in animal inhalation studies.

    Multifunctional Lipid Polymer Hybrid Nanocarriers in Cancer Therapy: Recent Developments and Challenges · 2026 · DOI

  • FST-loaded LPHNPs (F3) demonstrated sustained release for up to 48 hours in phosphate buffer at pH 7.4, but the formulation has only been evaluated in acute pancreatitis models in rats; clinical translation and efficacy validation in human pancreatic tissue or comparative studies with existing pancreatitis therapeutics are absent.

    Multifunctional Lipid Polymer Hybrid Nanocarriers in Cancer Therapy: Recent Developments and Challenges · 2026 · DOI

  • large-scale production The study proposes numerous areas for further research and development to fully exploit the potential of nanocarrier-based DTX delivery systems. Future research should prioritize enhancing the stability and scalability of these formulations to guarantee consistent in performance and enable industrial settings. Furthermore, extensive in-vivo investigations are to have a deeper understanding of the long-term destiny, metabolism, and possible these nanocarriers. Further improvements in targeting techniques, such as the integration of numerous targeting ligands and the investigation of novel biomaterials, have the potential to enhance the precision and effectiveness of these systems.

    Innovative Nanocarrier Strategies for Enhanced Docetaxel Delivery in Cancer Therapy · 2026 · DOI

  • The therapeutic potential of DOX to reach tumor-specific concentrations following post-systemic administration is limited, owing to its life-threatening cardiotoxicity.

    Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm · 2025 · DOI

  • The study measured doxorubicin release exclusively using intrinsic fluorescence spectrophotometry at 488 nm. Validation using orthogonal quantification methods (HPLC, mass spectrometry) or real-time imaging of nanoparticle degradation and drug release in live cells would strengthen characterization of the release mechanism and rule out fluorescence quenching artifacts.

    Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin · 2018 · DOI

  • The supporting information documents maximum theoretical doxorubicin encapsulation calculations but does not provide actual encapsulation efficiency percentages or compare encapsulation performance across different nanoparticle synthesis batches or surface coating variations, limiting reproducibility and scale-up assessment for clinical translation.

    Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin · 2018 · DOI

  • The paper does not investigate the mechanistic basis for superior tumor cell kill in doxorubicin-resistant TNBC subtypes. Specific investigation of whether the nanoparticle platform overcomes resistance via enhanced cellular uptake, bypassing efflux pumps (MDR1/P-glycoprotein), altered intracellular trafficking, or enhanced drug release is absent and critical for rational optimization.

    Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin · 2018 · DOI

  • The in vitro release kinetics were measured at only two temperatures (4°C and 37°C) in phosphate buffered saline at pH 7.4. The paper does not characterize doxorubicin release profiles under acidic conditions (pH 5.0-6.5) present in tumor microenvironments or within lysosomal compartments, which may critically determine intracellular bioavailability and efficacy in TNBC cells.

    Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin · 2018 · DOI

  • The study evaluated nanoparticle-encapsulated doxorubicin only in three triple-negative breast cancer cell lines (MD-MB-157, Hs578T, MDA-MB-468) plus one BRCA-mutant line (SUM149PT). Validation across a broader panel of TNBC subtypes with distinct molecular profiles and drug resistance mechanisms is needed to establish whether the nanoparticle delivery approach provides consistent superiority across the heterogeneous TNBC landscape.

    Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin · 2018 · DOI

  • Further research on oral delivery of PLGA NPs as well as distribution beyond 24 h is needed to fully understand particle behavior in vivo for successful application of NPs in drug delivery.

    The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats · 2013 · DOI

  • dosing regimens and extended observation periods will be required to evaluate the durability of the therapeutic response and to determine the optimal treatment schedule…

    Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy · 2026 · DOI

  • However, considering the amphiphilic nature of HupA, the encapsu- lation efficiency of hydrophobic polyester and hydrophilic hydrogel delivery systems is insufficient.

    A smart polyhydroxyalkanoate-hyaluronic acid hybrid biphasic delivery platform for enhanced Alzheimer’s symptom management via sustained huperzine A release · 2026 · DOI

  • This variability is thought to arise from heterogeneity in "bio-nano" interactions, yet the upstream drivers of these interactions are poorly defined.

    The gut microbiota regulates the protein corona formation, biodistribution, and cellular uptake of lipid nanoparticles · 2026 · DOI

Most-cited papers in Nanoparticle-Based Drug Delivery

Most recent work

Find a gap in your own Nanoparticle-Based Drug Delivery sub-topic

This page shows what the Nanoparticle-Based Drug Delivery literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Materials Science

Machine Learning in Materials Science
105 open questions
Nanoparticles: synthesis and applications
87 open questions
2D Materials and Applications
45 open questions
Natural Fiber Reinforced Composites
35 open questions
43 open questions have been extracted from the limitations and future-work passages of 437 Nanoparticle-Based Drug Delivery papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.